(CercleFinance.com) – Barclays reaffirms its ‘overweight’ recommendation and raises its price target from 95 to 105 euros on Sanofi, ‘the figures having already been reset, on the back of a solid R&D day’ and what it considers as a ‘continued positive dynamic for Dupixent’.
For the quarter, the broker says it is 2% below the consensus on sales, and in line with it on the EPS of activities, and for 2024, it declares itself ‘in line on both indicators (but above concerning products that matter)’.
Copyright © 2024 CercleFinance.com. All rights reserved.
The information and analyzes distributed by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends using the buttons below.
